These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1400931)

  • 1. Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Hum Reprod; 1992 Sep; 7(8):1085-9. PubMed ID: 1400931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Spanos E; Mantalenakis S
    Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development.
    Ergür AR; Yergök YZ; Ertekin A; Küçük T; Müngen E; Tütüncü L
    J Reprod Med; 1998 Mar; 43(3):185-90. PubMed ID: 9564642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome.
    Hugues JN; Cédrin-Durnerin I; Avril C; Bulwa S; Hervé F; Uzan M
    Hum Reprod; 1996 Dec; 11(12):2581-4. PubMed ID: 9021354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome.
    Larsen T; Larsen JF; Schiøler V; Bostofte E; Felding C
    Fertil Steril; 1990 Mar; 53(3):426-31. PubMed ID: 2106449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation induction with low-dose follicle-stimulating hormone in women with the polycystic ovary syndrome.
    Dale O; Tanbo T; Lunde O; Abyholm T
    Acta Obstet Gynecol Scand; 1993 Jan; 72(1):43-6. PubMed ID: 8382432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome.
    Sagle MA; Hamilton-Fairley D; Kiddy DS; Franks S
    Fertil Steril; 1991 Jan; 55(1):56-60. PubMed ID: 1898891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome.
    Farhi J; Jacobs HS
    Fertil Steril; 1997 Mar; 67(3):459-62. PubMed ID: 9091330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of clomiphene citrate-resistant polycystic ovarian syndrome with pure follicle-stimulating hormone or human menopausal gonadotropin.
    McFaul PB; Traub AI; Thompson W
    Fertil Steril; 1990 May; 53(5):792-7. PubMed ID: 2110070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Nugent D; Vandekerckhove P; Hughes E; Arnot M; Lilford R
    Cochrane Database Syst Rev; 2000; (4):CD000410. PubMed ID: 11034687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Hum Reprod; 1998 Mar; 13(3):567-70. PubMed ID: 9572412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome.
    Tanbo T; Dale PO; Kjekshus E; Haug E; Abyholm T
    Fertil Steril; 1990 May; 53(5):798-803. PubMed ID: 2110071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome.
    Weiss NS; Nahuis M; Bayram N; Mol BW; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2015 Sep; (9):CD010290. PubMed ID: 26350625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM; Lanzone A; Guida C; Nicoletti MC; Rossi P; Le Donne M; Caruso A; Mancuso S
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in patients with polycystic ovary syndrome.
    Nakamura Y; Yamada H; Yoshida K; Manno T; Ubukata Y; Suzuki M; Yoshimura Y
    Horm Res; 1990; 33 Suppl 2():43-8. PubMed ID: 2128881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu.
    Cassidenti DL; Paulson RJ; Lobo RA; Sauer MV
    Hum Reprod; 1992 Mar; 7(3):344-8. PubMed ID: 1587939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome.
    Homburg R; Levy T; Ben-Rafael Z
    Fertil Steril; 1995 Apr; 63(4):729-33. PubMed ID: 7890055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease.
    van Weissenbruch MM; Schoemaker HC; Drexhage HA; Schoemaker J
    Hum Reprod; 1993 Jun; 8(6):813-21. PubMed ID: 8345068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.
    Marci R; Senn A; Dessole S; Chanson A; Loumaye E; De Grandi P; Germond M
    Fertil Steril; 2001 Jun; 75(6):1131-5. PubMed ID: 11384638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.